There is increased risk for major gastrointestinal bleeding with edoxaban vs VKA therapy in patients with atrial fibrillation following TAVR.

Compared with warfarin, non-vitamin K antagonist oral anticoagulants (NOACs) are associated with lower rates of stroke and/or systemic embolism (SE) but varying rates of major bleeding in patients ...

Restricted mean survival time was 1,599 days among those assigned rivaroxaban and 1,675 among those assigned a vitamin K antagonist (difference, –76 days; 95% CI, –121 to –31; P < .001 for ...

“Non-vitamin K antagonist oral anticoagulants are recommended in international guidelines as broadly preferrable to vitamin K antagonists in the vast majority of patients with AF since the ...

DOACs or Vitamin K Antagonists for Patients ≥ 85 With AF and Recent Stroke? Mauricio Wajngarten, MD. January 03, 2023. Atrial fibrillation (AF) becomes more prevalent with increasing age, and ...

Use of vitamin K antagonists are linked to significantly higher risk for death or acute neurosurgery after traumatic brain injury vs direct oral anticoagulants or adenosine diphosphate inhibitors.

The Food and Drug Administration (FDA) has approved Balfaxar ® (prothrombin complex concentrate, human-Ians) for the urgent reversal of acquired coagulation factor deficiency induced by vitamin K ...

TCT 362: Direct-acting Oral Anticoagulants versus Vitamin K Antagonists in Patients Undergoing Transcatheter Aortic Valve Replacement: A Systematic Review and Meta-analysis. Presenter: Khawaja Akhtar.

Warfarin, also known by its brand name Coumadin, is what’s referred to as a vitamin K antagonist: It reduces clotting by interfering with vitamin K’s clot-promoting function.

Vitamin K deficiency may have a role in the development of calciphylaxis, ... We and others have previously reported that warfarin, a vitamin K antagonist, is a risk factor for calciphylaxis.

Vitamin K supplementation was associated with reduced evidence of cognitive impairment, ... especially in those treated with vitamin K antagonists,” said El-Sherbiny.